The primary aim of INDIGO is to prolong the time from diagnosis after surgery to the need for subsequent cytotoxic treatments in patients with residual or recurrent grade 2 gliomas with an IDH1 or IDH2 mutation between 1 and 5 years after the last surgery. The gene discussed is IDH1; the disease is glioma.